NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
13 trialsNCT01711632 2025-10-20
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04462471 2025-09-08
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03101254 2024-07-17
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01942993 2020-09-30
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01512251 2020-08-17
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
University of California, San Francisco
Phase 1/2 Completed
NCT02354690 2020-03-23
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01813214 2019-02-26
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
Phase 2 Terminated
NCT02050321 2018-12-26
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
University of Arizona
Phase 2 Terminated
NCT01495988 2017-10-24
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium
Phase 2 Terminated
NCT01754376 2017-04-12
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
Massachusetts General Hospital
Phase 2 Terminated
NCT01781026 2017-03-10
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Yale University
Phase 2 Completed
NCT01474551 2015-11-18
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated